Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Naltrexone + Bupropion and CBT for Weight Loss and Smoking Cessation in Pre-Bariatric Surgery Patients
NCT07224087Phase 1Not yet recruiting
- Sponsor
- Medical University of South Carolina
- Start
- Oct 2026
- Primary completion
- Dec 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of naltrexone and bupropion in obesity and nicotine dependence, sponsored by Medical University of South Carolina. Primary endpoints: Study enrollment to assess Feasibility at 16 weeks, Mean number treatment sessions attended to assess Feasibility at 16 weeks and 5 more. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
naltrexonebupropion
03
Conditions
obesitynicotine dependence
Beyond the preview
Go deeper on NCT07224087.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07224087.